

BACKGROUND


- Dementia is used to describe several diseases that affect neurocognitive functions.
- Over 733,000 Canadians currently live with dementia.
- 1,000,000 Canadians are projected to be living with dementia by 2030.
- Alzheimer's Disease (AD) is the most common form of dementia that primarily affects the aging population.
- AD is defined by cognitive symptoms interfering with social functioning and instrumental activities of daily living.
- The molecular pathology of AD begins decades before cognitive decline becomes apparent.
- Subjective Memory Complaints (SMCs) refers to an individuals' perception of their own or a loved one's cognitive impairment.
- SMCs may precede objective memory impairment, measured in neurocognitive assessments.
- Neurocognitive assessments assess objective cognitive performance.
- Since SMCs can be more apparent early in the disease course compared to some neurocognitive tests, they are a potentially valuable screening tool for AD.
- SMC screening would identify older adults that require further formal neurocognitive assessments and early management.
- Cognitive decline is often underdiagnosed due to challenges in administering objective tools.
- Subjective self-reported impairment is easier to administer and less costly.
- SMCs are useful for identifying at-risk patients for Mild Cognitive Impairment (MCI), an early manifestation of AD.
- Systemically comparing the neurocognitive test scores and SMCs of patients at the Osler Memory Clinic will help identify if SMCs can be integrated into the diagnosis process.
- Including self-reported data will minimize test administration challenges and reduce costs.

Subjective Memory

Recalling information with interpretations, emotions, and biases added to the memory. It includes personal feelings, and opinions about the remembered event.

Objective Memory

The ability to recall the specific facts. Information is recalled with accuracy, impartiality, and reliability.



OBJECTIVES

Examine the interaction between SMC and objective measures of cognitive performance.

Assess cognitive differences in population of older adults (i.e. age, gender) presenting to Osler's Memory Clinic based on a review of standardized assessments.

Ascertain SMC and correlations to objective tests of memory



Summarize differential associations between subjective and objective memory

STUDY DESIGN

Investigate if SMC can be used as a useful tool for identifying neurocognitive impairments through a retrospective chart review






Inclusion	Exclusion
Patients seen in Memory Clinic between April 1st, 2022 and March 31, 2024.	Patients seen in Seniors Ambulatory Clinics instead of Memory Clinic
Patients referred to Memory Clinic through a referral from a family physician and / or self-referral.	Patients that were last seen in the Memory Clinic outside of timeline



Neurocognitive Assessments	Cognitive Cutoff Score
Montreal Cognitive Assessment (MOCA)	< 26 / 30
MOCA-Blind	< 18 / 22
Geriatric Depression Scale (GDS)	> 9 / 15
Rockwood (Clinical) Frailty Scale	> 5 / 9
Mini Mental State Examination (MMSE)	< 26 / 30
Rowland Universal Dementia Assessment Scale (RUDAS)	< 23 / 30
Clock Drawing Test (CDT)	< 14.5 / 20

RESULTS



Variables in the Equation						
Subjective Decline Criteria (SDC)						
Subjective decline in memory, rather than other domains of cognition	Gender	B	S.E.	Wald	df	Sig.
	Age	-0.020	0.030	0.460	1	0.498
	MOCA Total Score	-0.055	0.028	3.902	1	0.048*
	Constant	4.057	2.553	2.526	1	0.112
	57.780					
Onset of SCD within the last 5 years						
	Gender	-0.237	0.344	0.476	1	0.490
	Age	0.014	0.027	0.283	1	0.595
	MOCA Total Score	0.006	0.024	0.055	1	0.815
	Constant	-2.403	2.240	1.151	1	0.283
	0.090					
Age at onset of SCD > 60 years old						
	Gender	0.345	0.431	0.639	1	0.424
	Age	-0.039	0.034	1.349	1	0.246
	MOCA Total Score	-0.027	0.031	0.766	1	0.381
	Constant	5.396	2.868	3.540	1	0.060
	220.568					
Particular concerns (worries) associated with SCD						
	Gender	-0.206	0.330	0.391	1	0.532
	Age	-0.048	0.026	3.542	1	0.060
	MOCA Total Score	-0.035	0.023	2.238	1	0.135
	Constant	5.439	2.186	6.194	1	0.013
	230.271					
Feeling of worse performance than others of the same age group						
	Gender	-0.063	0.397	0.025	1	0.873
	Age	0.026	0.030	0.751	1	0.386
	MOCA Total Score	0.027	0.028	0.924	1	0.336
	Constant	-4.234	2.580	2.693	1	0.101
	0.014					
Confirmation of perceived cognitive decline by an informant						
	Gender	-0.309	0.370	0.700	1	0.403
	Age	-0.039	0.027	2.055	1	0.152
	MOCA Total Score	-0.085	0.026	10.314	1	0.001*
	Constant	5.979	2.359	6.424	1	0.011
	394.934					

Variables in the Equation						
Patients expressing over 50% of SDC						
	Gender	B	S.E.	Wald	df	Sig.
	Age	-0.052	0.024	4.629	1	0.0314*
	MOCA Total Score	-0.049	0.022	4.986	1	0.0256*
	Constant	5.464	2.048	7.115	1	0.008
	235.968					

DISCUSSION

- All patients are over 65 years old
- 56% of patients are between the ages of 80-89
- The mean age is 82.8, n=300
- MOCA and RUDAS were administered for 52% and 25% of cases respectively; n=389.
- The most relevant SMC included: misplacing items, repetition, increased anxiety, and poor memory.
- 69% of patients in Osler's Memory Clinic express more than half of the SDC (Molinuevo et al.).
- Since the odds ratio of Exp(B) is less than 1, a 1 point increase in MOCA score leads to a decrease in the likelihood of reporting subjective memory complaints or confirmation of cognitive decline.
- Contrary to literature, age did not have an impact on SMC or confirmation of cognitive decline since the odds ratio of Exp(B) is not significant (likely attributed to sample size).

NEXT STEPS

- Investigate the relationship between SMCs and ethnicity to discover early predictors of dementia in ethnically diverse subgroups that Osler serves.
- Study the prevalence of specific self-reported SMCs based on age and gender.
- Further work on representative sample with a larger sample size to confirm associations in the characteristics

ACKNOWLEDGEMENTS

- Seniors' Health Program
- Osler Research Institute for Health Innovation
- Toronto Metropolitan University

REFERENCES

Alzheimer Society of Canada. (n.d.). Navigating the Path Forward for Dementia in Canada: The Landmark Study Report #1. Alzheimer Society of Canada. Retrieved August 15, 2024, from <https://alzheimer.ca/en/research/reports-dementia/landmark-report-1>

Aprahamian, I., Martelli, J. E., Neri, A. L., & Yassuda, M. S. (2009). The Clock Drawing Test: A review of its accuracy in screening for dementia. *Dementia & Neuropsychologia*, 3(2), 74-81. <https://doi.org/10.1590/S1980-57642009DN030200002>

Daniel, B., Agenagnaw, L., Workicho, A., & Abera, M. (2022). Validation of the Rowlands Universal Dementia Assessment Scale (RUDAS) to detect major neurocognitive disorder among elderly people in Ethiopia, 2020. *PloS One*, 17(1), e0262483. <https://doi.org/10.1371/journal.pone.0262483>

Davis, D. H., Creavin, S. T., Yip, J. L., Noel-Storr, A. H., Brayne, C., & Cullum, S. (2021). Montreal Cognitive Assessment for the detection of dementia. *The Cochrane Database of Systematic Reviews*, 2021(7), CD010775. <https://doi.org/10.1002/14651858.CD010775.pub3>

Laudisio, A., Antonelli Incalzi, R., Gemma, A., Marzetti, E., Pozzi, G., Padua, L., Bernabei, R., & Zuccala, G. (2018). Definition of a Geriatric Depression Scale cutoff based upon quality of life: A population-based study. *International Journal of Geriatric Psychiatry*, 33(1), e58-e64. <https://doi.org/10.1002/gps.4715>

Mendraitas, P., Schoo, C., & Lati, R. (2024). Clinical Frailty Scale. In StatPearls. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK559009/>

Modarres, M. H., Kalafatis, C., Apostolou, P., Tabet, N., & Khaligh-Razavi, S.-M. (2023). The use of the integrated cognitive assessment to improve the efficiency of primary care referrals to memory services in the accelerating dementia pathway technologies study. *Frontiers in Aging Neuroscience*, 15, 1243316. <https://doi.org/10.3389/fnagi.2023.1243316>

Molinuevo, J. L., Rabin, L. A., Amariglio, R., Buckley, R., Dubois, B., Ellis, K. A., Ewers, M., Hampel, H., Klöppel, S., Rami, L., Reisberg, B., Saykin, A. J., Sikkes, S., Smart, C. M., Snitz, B. E., Sperling, R., van der Flier, W. M., Wagner, M., Jessen, F., & Subjective Cognitive Decline Initiative (SCD-I) Working Group. (2017). Implementation of subjective cognitive decline criteria in research studies. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 13(3), 296-311. <https://doi.org/10.1016/j.jalz.2016.09.012>

Salis, F., Costagutti, D., & Mandas, A. (2023). Mini-Mental State Examination: Optimal Cut-Off Levels for Mild and Severe Cognitive Impairment. *Geriatrics*, 8(1), 12. <https://doi.org/10.3390/geriatrics8010012>

Wasef, S., Laksono, I., Kapoor, P., Tang-Wei, D., Gold, D., Saripella, A., Razi, S., Islam, S., Englesakis, M., Wong, J., & Chung, F. (2021). Screening for subjective cognitive decline in the elderly via subjective cognitive complaints and informant-reported questionnaires: A systematic review. *BMC Anesthesiology*, 21(1), 277. <https://doi.org/10.1186/s12871-021-01493-5>